AstraZeneca (ADR)
Develops oncology-led medicines spanning rare diseases, cardiovascular care, metabolism, respiratory disease, and immunology.
Something off on this page? Send us feedback.
Profile
Develops prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Sold in more than 125 countries, the portfolio is oncology-led and shaped by clinical evidence, regulatory approval, patent exclusivity, supply execution, and reimbursement.
Develops and commercializes prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism and Respiratory & Immunology. The portfolio is sold in more than 125 countries, with oncology now the primary growth and research engine.
Science-led portfolio selection concentrates resources on drug candidates through staged development decisions. Antibody-drug conjugates, immuno-oncology, cell therapy, multispecific antibodies, rare-disease biologics, and AI-enabled discovery extend a base rebuilt after major patent expiries.
Performance depends on clinical evidence, regulatory approvals, manufacturing and supply execution, patent exclusivity, and pricing and reimbursement rules. Pending proceedings involving the China subsidiary add a current legal and compliance dependency, while the allegations remain unresolved.
Company facts
Key statistics
Year to date −10.9% · Average volume (30d) 3.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Aug 23, 2026 | CICC | Initiate | Outperform | ||
| Jul 13, 2026 | HSBC | Downgrade | Buy | Hold | |
| Jul 9, 2026 | KeyBanc | Downgrade | Sector Weight | ||
| Dec 10, 2025 | HSBC | Target | $108 | ||
| Dec 3, 2025 | Morgan Stanley | Target | $103 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026Q2 FY26 | $2.50 | $2.63 | +5.2% | $15.44B | $15.38B | −0.3% | +1.67% |
| Apr 29, 2026Q1 FY26 | $2.57 | $2.58 | +0.4% | $14.93B | $15.29B | +2.4% | +1.17% |
| Feb 10, 2026Q4 FY25 | $2.09 | $2.12 | +1.4% | $15.44B | $15.50B | +0.4% | +6.04% |
| Nov 6, 2025Q3 FY25 | $2.28 | $2.38 | +4.4% | $14.78B | $15.19B | +2.8% | −1.67% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $13.59B | $14.46B | $15.19B | $15.50B | $15.29B | $15.38B | |
| Gross profit | $11.35B | $11.98B | $12.39B | $12.39B | $12.61B | $12.86B | |
| Operating income | $3.67B | $3.51B | $3.58B | $2.98B | $4.25B | $3.16B | |
| Net income | $2.92B | $2.45B | $2.53B | $2.33B | $3.08B | $2.51B | |
| Diluted EPS | $1.87 | $1.57 | $1.62 | $1.48 | $1.97 | $1.59 | |
| Gross margin | 83.5% | 82.9% | 81.6% | 79.9% | 82.5% | 83.6% | |
| Operating margin | 27.0% | 24.3% | 23.6% | 19.2% | 27.8% | 20.6% |
Fiscal years (4-quarter sums)FY21 $37.42B · FY22 $44.35B · FY23 $45.81B · FY24 $54.07B · FY25 $58.74B
Revenue by product · FY25
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $4.96B · Total debt $32.20B · Total assets $115.70B · Shareholders' equity $50.24B
Dividends
Raised for 6 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 7, 2026 | Aug 7 | Sep 8 | $1.06 | cut from $2.17 |
| Feb 20, 2026 | Feb 20 | Mar 23 | $2.17 | raised from $1.03 split-adjusted |
| Aug 8, 2025 | Aug 8 | Sep 8 | $0.515 | cut from $1.05 |
| Feb 21, 2025 | Feb 21 | Mar 24 | $1.05 | raised from $0.50 |
| Aug 9, 2024 | Aug 9 | Sep 9 | $0.50 | cut from $0.985 |
| Feb 22, 2024 | Feb 23 | Mar 25 | $0.985 | raised from $0.465 |
| Aug 10, 2023 | Aug 11 | Sep 11 | $0.465 | cut from $1.97 split-adjusted |
| Feb 23, 2023 | Feb 24 | Mar 27 | $0.965 | raised from $0.455 |
Ownership
Shares outstanding 1.55B · Float 1.54B · 99.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Investor AB | 51.59M | 3.33% | 13F | Aug 14, 2026 |
| Vanguard Capital Management LLC | 45.39M | 2.93% | 13F | Aug 13, 2026 |
| Capital International Investors | 34.58M | 2.23% | 13F | Aug 12, 2026 |
| Norges Bank | 33.86M | 2.18% | 13F | Aug 12, 2026 |
| Capital World Investors | 30.08M | 1.94% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 20, 2026 | Mani Sharma | officer: See Remarks | −11,893 | $185.78 |
Peers
- Merck
Leads a rival immunotherapy franchise across major solid tumors
- Bristol-Myers Squibb
Contests multiple lung, liver, and gastrointestinal cancer markets
- GSK (ADR)
Competes in endometrial immunotherapy and ovarian PARP maintenance
- Novartis (ADR)
Competes in PNH complement therapy and severe-asthma biologics
- Pfizer
Overlaps in breast and bladder cancer therapeutics
- Eli Lilly
Overlaps in CLL/SLL treatment and type 2 diabetes
- Sanofi (ADR)
Biologic rival in eosinophilic asthma
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Median | 36.9 | 13.4 | 2.8 | +5.1% |